High-Yield Psychiatry for USMLE Step 3: Depression, Psychosis, and Substance Use

Most people walk into Step 3 thinking psychiatry is the "easy" section. Then they bomb a CCS case because they gave an antidepressant to an unscreened bipolar patient and triggered mania. I've seen it happen dozens of times. Psychiatry on this exam isn't about pattern-matching DSM criteria — it's about knowing which prescription will hurt your patient and which emergency will kill them if you hesitate.

Here's what actually shows up, and what trips people up.

Mood Disorders

Major Depressive Disorder (MDD)

Diagnosis: 5+ symptoms for ≥ 2 weeks, and at least one must be depressed mood OR anhedonia. The rest — sleep changes, appetite/weight shifts, fatigue, poor concentration, psychomotor changes, worthlessness/guilt, suicidal ideation — fill out the picture.

First-line treatment: SSRIs (sertraline, escitalopram, fluoxetine).

A few things that trip examinees up on timing:

• Full therapeutic effect takes 4–6 weeks. Not days. Not two weeks. The exam loves asking about the patient who "isn't responding" at week three. The answer is almost always: stay the course.
• Give a real trial — 6 to 8 weeks — before calling it a failure.
• Partial response at 4–6 weeks? Bump the dose.
• No response at all? Switch SSRIs or augment with lithium, an atypical antipsychotic, or bupropion.

Choosing the right antidepressant by comorbidity is bread-and-butter Step 3:

• Chronic pain: SNRIs (duloxetine, venlafaxine) or TCAs (amitriptyline)
• Can't sleep: mirtazapine or trazodone — both sedate
• Worried about sexual side effects: bupropion (zero sexual dysfunction, doubles as smoking cessation)
• Smoking cessation: bupropion or varenicline

The pearl that saves you a question: Before you prescribe any antidepressant, screen for bipolar. Two questions: "Have you ever had a period where you were unusually energetic or needed almost no sleep?" and "Does bipolar disorder run in your family?" Antidepressant monotherapy in undiagnosed bipolar triggers mania. The exam tests this repeatedly because physicians in practice miss it constantly.

Bipolar Disorder

Bipolar I: one manic episode (≥ 7 days, or any duration if hospitalization is required). That's it. You don't need a depressive episode for the diagnosis — a fact that surprises a lot of test-takers.

Bipolar II: hypomanic episodes (4–7 days, never requiring hospitalization) plus at least one major depressive episode.

Cyclothymia: milder swings on both sides, lasting ≥ 2 years continuously.

Mood stabilizers — know the table cold:

Drug	Primary Indication	Key Monitoring
Lithium	Bipolar I (mania + depression), suicide prevention	Narrow therapeutic index; levels 0.6–1.2 mEq/L; monitor renal function, TSH. Toxicity: tremor, nephrogenic DI, hypothyroidism
Valproate	Mania, rapid cycling, mixed states	LFTs; highly teratogenic (neural tube defects) — contraception is mandatory; thrombocytopenia
Lamotrigine	Bipolar depression (NOT mania)	Titrate slowly or risk SJS. Risk jumps when co-administered with valproate
Atypical antipsychotics	Acute mania	Metabolic syndrome screening

Acute mania: benzodiazepines (lorazepam) buy you time for rapid sedation while you load a mood stabilizer or antipsychotic. Don't try to talk a manic patient into calm — sedate first, stabilize second.

Psychotic Disorders

Schizophrenia

Diagnosis: ≥ 2 of the following — hallucinations, delusions, disorganized speech, disorganized/catatonic behavior, negative symptoms — persisting ≥ 6 months with functional decline.

Here's the conceptual framework worth internalizing:

Positive symptoms (dopamine excess, mesolimbic pathway): hallucinations, delusions, disorganized thinking. These are what medications treat best.

Negative symptoms (dopamine deficit, mesocortical pathway): flat affect, alogia, avolition, anhedonia, social withdrawal. These are what actually predict long-term disability — and what our drugs barely touch. When the exam gives you a patient on adequate antipsychotic dosing whose "voices are gone but he still won't leave his room," they're testing whether you understand this distinction.

Atypical (second-generation) antipsychotics are first-line. Know each drug's signature side effect:

Drug	Side Effects to Know
Risperidone	Highest EPS risk among atypicals; hyperprolactinemia
Olanzapine	Worst metabolic profile — weight gain, diabetes, dyslipidemia
Quetiapine	Sedating; minimal EPS; moonlights as a sleep aid and depression adjunct
Aripiprazole, ziprasidone	Cleanest metabolic profile
Clozapine	Reserved for treatment-resistant cases ONLY; agranulocytosis (mandatory ANC monitoring); seizures; myocarditis

Contrarian take: I think the exam over-emphasizes clozapine relative to clinical practice, but that's precisely why you need to know it. In real life, most psychiatrists delay clozapine far too long in treatment-resistant patients. On Step 3, though, the moment a vignette says "failed two adequate antipsychotic trials," the answer is clozapine. Don't overthink it.

Neuroleptic Malignant Syndrome (NMS)

This kills people. Know it reflexively.

Presentation: hyperthermia (> 40°C), lead-pipe rigidity (this is the buzzword), altered consciousness, autonomic instability (labile BP, tachycardia, diaphoresis), massively elevated CK.

Management:

1. Stop the antipsychotic — immediately, no exceptions
2. Aggressive IV hydration + cooling
3. Dantrolene (relaxes skeletal muscle)
4. Bromocriptine (restores dopamine activity)
5. ICU. Full stop.

NMS vs. serotonin syndrome — the distinction the exam loves:

Feature	NMS	Serotonin Syndrome
Hallmark	Lead-pipe rigidity	Clonus + hyperreflexia
Onset	Slow (days)	Fast (hours)
Trigger	Antipsychotic started or increased	Serotonergic drug combination
Treatment	Dantrolene + bromocriptine	Cyproheptadine + benzodiazepines

If you remember nothing else: rigidity = NMS, clonus = serotonin syndrome.

Substance Use Disorders

Alcohol Withdrawal Timeline

This timeline gets tested in some form on virtually every Step 3 administration. Memorize it.

Symptoms	Timing
Tremors, anxiety, insomnia	6–24 hours
Alcoholic hallucinosis (visual/auditory, intact sensorium)	12–24 hours
Withdrawal seizures	12–48 hours
Delirium tremens	48–96 hours (autonomic instability + true delirium — this one kills)

CIWA scale drives treatment intensity. Benzodiazepines are first-line for every stage of alcohol withdrawal — no debate.

• Long-acting (diazepam, chlordiazepoxide): self-tapering pharmacokinetics; use in most patients
• Short-acting (lorazepam, oxazepam): reach for these in liver disease and the elderly — "LOT" (Lorazepam, Oxazepam, Temazepam) skip hepatic metabolism

Give thiamine 100 mg IV BEFORE any glucose. I cannot stress this enough. Glucose without thiamine in a thiamine-depleted patient precipitates Wernicke encephalopathy. The exam specifically tests the order.

Wernicke encephalopathy triad: confusion, ataxia, ophthalmoplegia (nystagmus, lateral gaze palsy). Treat aggressively — high-dose IV thiamine, 500 mg TID for 3 days minimum.

Korsakoff syndrome is what happens when Wernicke goes untreated. Anterograde amnesia dominates, patients confabulate to fill gaps, and the damage is largely permanent. It's one of the most preventable tragedies in medicine.

Opioid Withdrawal and Overdose

Overdose triad: miosis (pinpoint pupils), respiratory depression, depressed consciousness → give naloxone IM or intranasal. Repeat every 2–3 minutes as needed. Then watch the patient — naloxone's half-life is shorter than most opioids, and re-narcotization catches people off guard.

Withdrawal is miserable but not lethal (unlike alcohol and benzos). Look for symptoms that are the physiologic opposite of opioid intoxication: mydriasis, tachycardia, diarrhea, piloerection, yawning, muscle aches, anxiety.

Surprising fact that changes your clinical framing: opioid withdrawal won't kill an otherwise healthy adult. Alcohol and benzodiazepine withdrawal can. The exam uses this distinction to test whether you'll emergently manage a patient in opioid withdrawal (you shouldn't — supportive care and medication-assisted treatment) versus alcohol withdrawal (you must — benzos, monitoring, ICU if needed).

Opioid use disorder treatment options:

• Buprenorphine/naloxone (Suboxone): partial μ-opioid agonist; reduces cravings; prescribable in outpatient settings
• Methadone: full agonist; must be dispensed at licensed clinics; carries highest overdose risk if diverted
• Naltrexone (Vivitrol): opioid antagonist; blocks the high; patient must be fully detoxed first or you'll precipitate withdrawal; works best in highly motivated patients

Psychiatric Emergencies

Involuntary Hospitalization

Jurisdictions vary, but Step 3 tests general principles. You need at least one of:

1. Danger to self — active suicidal ideation with plan, intent, or recent attempt
2. Danger to others — credible, specific, imminent threat toward an identifiable person
3. Grave disability — unable to meet basic survival needs (food, shelter, safety) due to mental illness

Suicide risk assessment: distinguish passive ideation ("I wish I wouldn't wake up") from active ideation with plan, intent, and means access. High-risk features to flag: male sex, prior attempts, firearm access, hopelessness, active substance use, social isolation. When the exam gives you a patient with multiple risk factors, the answer is almost never "outpatient follow-up in two weeks."

Frequently Asked Questions

How many psychiatry questions should I expect on Step 3?

Psychiatry typically accounts for 5–8% of the exam. You'll see it in both multiple-choice and CCS cases. The CCS psychiatry cases are where most points are lost because timing of interventions matters — ordering the wrong lab sequence or prescribing before screening for bipolar are common errors that the scoring algorithm catches.

Should I focus more on pharmacology or diagnosis for psychiatry on Step 3?

Pharmacology, without question. Step 3 assumes you can already identify major depression or schizophrenia from a vignette. What it really tests is: do you know which drug to pick for a specific patient profile, what side effects to monitor for, and what to do when the first-line fails? Drug selection by comorbidity and side-effect management are where the points live.

What's the highest-yield topic within psychiatry for Step 3?

Substance withdrawal timelines and management. I've reviewed hundreds of Step 3 score reports, and questions on alcohol withdrawal (especially the thiamine-before-glucose rule and DT timing) and opioid overdose reversal appear with remarkable consistency. Mood disorder pharmacology is a close second.

How do I handle a CCS case where a patient is suicidal?

Prioritize safety. Admit the patient, place on 1:1 observation, remove access to means (ask about firearms, medications at home), order a comprehensive metabolic panel, TSH, urine drug screen, and blood alcohol level. Consult psychiatry. Do NOT discharge with a safety plan alone if the patient has active ideation with a plan — the scoring algorithm penalizes this heavily.

Is it worth memorizing every antipsychotic side effect?

No. Know the extremes. Olanzapine = worst metabolic effects. Risperidone = most EPS among atypicals. Clozapine = agranulocytosis. Aripiprazole = cleanest profile. Quetiapine = sedating. That's the level of resolution Step 3 operates at. You're not matching a psychiatry board exam — you're proving you won't harm a patient with the wrong prescription.

Practice Psychiatry Questions

Ready to test yourself against realistic vignettes? Step3Sim offers free USMLE Step 3 practice questions for psychiatry and all other organ systems. The best way to lock in pharmacology is to get a question wrong, read the explanation, and see the same concept from a different angle three days later.